Whether a device or a drug company, a contract service provider, an adviser or an investor – you will already be aware that “off the shelf” insurance policies are not fit for purpose for the health and life science sectors.
In Howard Pearson we are privileged to have more than 25 years’ experience in arranging insurance for life science companies both sides of the Atlantic from start-up and spin out, to junior and senior stock exchanges.
Paul Dickson, CEO
The Boards of health and life science companies should initially focus on three things:
- Product liability and/or clinical trials liability requirements
- Supply chain dependencies, particularly where the supplier requires regulatory approval
- Directors personal exposure to litigation from investors
However almost every insurance policy will then need detailed attention – as unless using a specialist insurer the policy is unlikely to be adequate.